somatropin + glutamine

This therapeutic regimen consists of low-dose recombinant human growth hormone (somatropin) and the amino acid glutamine, typically administered in conjunction with a specialized high-carbohydrate, low-fat diet. Evaluated in clinical trials led by the University of Nebraska, this combination therapy is designed to treat short bowel syndrome (SBS) by promoting intestinal adaptation and enhancing nutrient absorption. Somatropin acts as an agonist at the growth hormone receptor, stimulating the production of insulin-like growth factor 1 (IGF-1), which induces the proliferation of intestinal mucosal cells and increases villus height. Glutamine serves as a primary metabolic fuel for enterocytes and supports mucosal integrity. The regimen specifically utilizes a lower dose of somatropin (0.05 mg/kg/day) than the standard FDA-approved dose for SBS, aiming to maintain efficacy in reducing total parenteral nutrition (TPN) dependence while minimizing growth hormone-related side effects.

Other names

low-dose somatropin + glutaminerecombinant human growth hormone + L-glutaminerhGH + glutamineGH + GLN + Diet